Exosome-Depleted UltraGRO™-PURE GI
Exosome-Depleted UltraGRO™-PURE GI

NewNew

For Therapeutic Cell-derived EV production
For Therapeutic Cell-derived EV production

Exosome-Depleted UltraGRO™-PURE GI

NEW

For Therapeutic Cell-derived EV production
AventaCell BioMedical Corp. has developed an exosome depletion process to remove human platelet
lysate (hPL)-derived exosomes. Exosome-Depleted
UltraGRO™-PURE GI (ED UG-P GI) is able to support
human MSC cell viability to secret abundant extracellular vesicles (EVs) without compromising phenotype over the culture period. Moreover, gammairradiation processing of the product is used as apathogen reduction treatment (PRT) for viral inactivation, to comply with regulatory guidance for clinical research and development.

BENEFITS OF EXOSOME-DEPLETEDULTRAGRO™-PURE GI•

Xeno-free with >95% nanoparticle removal fromthe hPL supplement•

Minimal hPL nanoparticle contamination•

MSCs cultured with the depleted supplement
remain highly viable with stable phenotype
markers throughout the culture period•

Exosome-Depleted UltraGRO™-PURE GI toproduce hMSC-derived EVs•Gamma irradiation processing is accepted byregulatory agencies as a validate

D
DeepplleetteeddhhPPLL

hhPPLL

1/1000 dilution
dilution
1/1000-MEM
edeida ia l aolnoene
αα-MEMmm

1/10
1/10dilution
dilution

1/10
dilution
1/10
dilution

Nanoparticles were analyzed by NTA. Nanoparticle size distribution in hPL product before and after the depletion process compared toα-MEM basal media alone. Results showed a significant particle removal of the particle signal after the depletion process. Moreover, the outstanding and consistent particle removal from each batch was performed in the study, resulting an average of 99% of depletion rate (n = 5).

NTA results (n = 5)

Non-depleted hPL

Depleted hPL

Depletion rate

Particle count/mL

2.73 x1011 ± 6.48 x1010

3.52 x109 ± 3.16 x109

99.07%

UC-MSC cell viability

1009080706050403020100100

10080

800%
2%

600%

402%

205%

Viability %BM-MSC cell viability

Viability %Viability %AD-MSC cell viability

602%

205%0Day 2 Day 4 Day 6
Culture period0%405%0Day 2 Day 4 Day 6
Culture period

Day 2 Day 4 Day 6
Culutre period

Cell viability of AD-, BM-, and UC-MSCs were monitored during the culture period. Target MSCs cultured in the presence of ED UG-P GI
showed >90% viable with continuous growth compared to α-MEM basal alone which presented a significant drop on day 2.

Secreted AD-MSC EVs
per cycle

Secreted BM-MSC-EVs
per cycle
Particle countParticle count5.0E+104.0E+103.0E+102.0E+10
1.0E+100.0E+00

Secreted UC-MSC-EVs
per cycle

1.2E+101.0E+108.0E+09
6.0E+09
4.0E+09
2.0E+09
0.0E+00

Cycle Cycle Cycle
1230% 2% 5%8.0E+10Particle countA6.0E+104.0E+102.0E+100.0E+00Cycle Cycle Cycle
1230% 2% 5%Cycle Cycle Cycle
1230% 2% 5%Total EV yield over 6 days per ﬂask

BUCMSC

5%
2%0%BMMSC
ADMSC
0.0E+00 3.0E+10 6.0E+10 9.0E+10 1.2E+11 1.5E+11 1.8E+11Particle count

Secreted MSC-derived EVs were collected from each production cycle and were analyzed by NTA. (A) EV secretion profile in each production
cycle, (B) total MSC-derived EV yield per T75 flask in 6 daysProduct NumberProductBottle Size (mL)

HPCHEFRLI05

Exosome-Depleted
UltraGRO™-PURE GI50

HPCHEFRLI50500

Reference: AventaCell ED UG-P GI_MSC Factsheet
Reference: AventaCell ED UG-P GI_MSC 2023 ISCT Poster